Overview

Wellbutrin XL for Dysthymic Disorder

Status:
Completed

Trial end date:
2008-06-01

Target enrollment:

Participant gender:

Summary

This is a ten-week, double-blind study of Wellbutrin XL in outpatients with dysthymic disorder, a form of low-grade chronic depression. We hypothesize that patients taking Wellbutrin XL will show greater improvement in depression symptoms and psychosocial functioning than patients taking placebo.

Phase:

Phase 4

Details

Lead Sponsor:

St. Luke's-Roosevelt Hospital Center

Collaborator:

GlaxoSmithKline

Treatments:

Bupropion